New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
09:38 EDTBDSIBioDelivery Sciences sales may jump on DEA move, says Summer Street
Summer Street believes the Drug Enforcement Agency's announcement yesterday that it will reschedule all hydrocodone combination products to schedule II from schedule III could allow BioDelivery Sciences's BEMA Buprenorphine to potentially reach significantly higher sales levels. The firm says BEMA Buprenorphine will now have an easier compare against Vicodin and generic equivalents. Summer Street has a Buy rating on BioDelivery with a $20 price target.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
17:12 EDTBDSIBroadfin Capital reports 7.33% passive stake in BioDelivery Sciences
May 14, 2015
19:02 EDTBDSIOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTBDSIEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use